In this context, the identification and characterization of the molecular profiles of KRAS-wild type metastatic PC with next-generation DNA/RNA sequencing, microsatellite instability (MSI), and mismatch repair status determination seem to be crucial to expand therapeutic options and offer targeted treatments in clinical practice. This evidence concerns the gene KRAS and pachyonychia congenita.